The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape

Affiliations

¹ State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
² State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. yuanjiahu@um.edu.mo.

Liyang Lyu et al. Nat Biotechnol. 2020 Dec.

. 2020 Dec;38(12):1387-1394.

doi: 10.1038/s41587-020-00749-8.

¹ State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
² State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China. yuanjiahu@um.edu.mo.

No abstract available

References

1. Hoos, A. Nat. Rev. Drug Discov. 15, 235–247 (2016). - DOI
1. Tang, J., Pearce, L., O’Donnell-Tormey, J. & Hubbard-Lucey, V. M. Nat. Rev. Drug Discov. 17, 783–784 (2018). - DOI
1. Tang, J., Hubbard-Lucey, V. M., Pearce, L., O’Donnell-Tormey, J. & Shalabi, A. Nat. Rev. Drug Discov. 17, 465–466 (2018). - DOI
1. Yip, A. & Webster, R. M. Nat. Rev. Drug Discov. 17, 161–162 (2018). - DOI
1. Centers for Medicare & Medicaid Services. Decision memo for chimeric antigen receptor (CAR) T-cell therapy for cancers (CAG-00451N) (2019); https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo...